Dare Bioscience develops women's health drugs and consumer products for areas such as contraception, menopause, and sexual health. It last closed at $0.43 on Nov 17, down 26.57% on the day.
Only 1 firm rated DARE in the past 90 days, not enough for a consensus
Average 12-month target
$2.00
▲ 366.2% upside
Based on 1 analyst who set a price target on DARE in the past 90 days. The average target is $2.00, with a high of $2.00 and a low of $2.00, compared with the last close of $0.43.
Low $2.00Avg $2.00High $2.00
Blue marker: last close $0.43
Highest target$2.00
Average target$2.00
Lowest target$2.00
Latest rating changes
Ladenburg ThalmannAssumed coverage
Oct 26Buy$2
Date
Firm
Action
Rating
Price target
Oct 26
Ladenburg Thalmann
Assumed coverage
Buy
$2
Loading…
Technical Analysis
DARE · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 51% below its 20 day and 68% below its 50 day average. It is 251% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the 52 week low at $0.41, and the nearest resistance the Pivot at $0.48.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 13.7%/day
Key levels
$3.7852 week high+779.1%
$1.50200 day average+248.8%
$1.03100 day average+139.5%
$0.7250 day average+67.4%
$0.71Swing high (Nov 11)+65.1%
$0.6520 day average+51.2%
$0.54Pivot R1+25.6%
$0.48Pivot+11.6%
$0.43Last close
$0.4152 week low−4.7%
$0.37Pivot S1−14.0%
Indicators
RSI (14)
21.57
Oversold below 30
Oversold
MACD
-0.05
Below its signal line
Bearish
Stochastic
11.9
Near the bottom of its range
Oversold
ADX (14)
24.4
Weak trend
Williams %R
-95.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-439.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−32.1%
Change over 10 sessions
Bearish
ATR (14)
$0.06
Typical daily range, 13.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 54.9%/day
Key levels
$3.7852 week high+779.1%
$1.50200 day average+248.8%
$1.03100 day average+139.5%
$0.7250 day average+67.4%
$0.71Swing high (Nov 11)+65.1%
$0.6520 day average+51.2%
$0.54Pivot R1+25.6%
$0.48Pivot+11.6%
$0.43Last close
$0.4152 week low−4.7%
$0.37Pivot S1−14.0%
Indicators
RSI (14)
30.10
Weak, oversold below 30
Neutral
MACD
-0.32
Below its signal line
Bearish
Stochastic
3.2
Near the bottom of its range
Oversold
ADX (14)
20.1
Weak trend
Williams %R
-97.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-89.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−39.2%
Change over 10 sessions
Bearish
ATR (14)
$0.24
Typical daily range, 54.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DARE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how DARE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow DARE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DARE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DARE is in one of them and how their past DARE trades turned out.
Dare Bioscience is a biotech company based in San Diego, California, that develops products for women's health. Its portfolio covers areas such as contraception, menopause, sexual health, pelvic pain, fertility, and vaginal health. The company plans to offer prescription products, compounded drugs, and consumer health products that do not need a prescription, mainly for women and the healthcare providers who treat them. Its first FDA-approved product, a treatment for bacterial vaginosis, is licensed to another drugmaker for sale.